FDA Orange Book
Is there a generic for Varithena?
Varithena contains polidocanol. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Varithena (polidocanol). The Orange Book shows its last listed patent expires May 12, 2032.
Run it in Rivvi
Map Varithena and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Varithena products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, intravenous | 180MG/18ML (10MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, intravenous | 77.5MG/7.75ML (10MG/ML) | Discontinued | None | 0 | None |
NDA 205098, held by BOSTON SCIENTIFIC CORP. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Varithena patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 7814943 | November 19, 2027 | Drug product | U-1461 | 205098 |
| 9480652 | May 12, 2032 | Drug product | None | 205098 |
Questions
Is there a generic for Varithena?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Varithena (polidocanol). The Orange Book shows its last listed patent expires May 12, 2032.
What is the generic name for Varithena?
The active ingredient in Varithena is polidocanol, per the FDA Orange Book.
When does the Varithena patent expire?
The last patent listed for Varithena in the Orange Book expires May 12, 2032. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.